(Q55192988)

English

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

1 reference

Europe PubMed Central

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. (English)

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

Adaptive radiation therapy

0 references

circulatory system

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

6

object named as

Nancy L Keating

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

author name string

Glenn N Levine

1

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

Anthony V D'Amico

2

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

Peter Berger

3

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

Robert H Eckel

5

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

Richard V Milani

7

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

Arthur I Sagalowsky

8

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

Matthew R Smith

9

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

Neil Zakai

10

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association

11

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

language of work or name

0 references

publication date

2 February 2010

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

60

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

3

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

194-201

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Rising PSA in nonmetastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

The metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Endocrine treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 June 2018

Duration of androgen suppression in the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Standards of medical care in diabetes--2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Insulin sensitivity during combined androgen blockade for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Changes in body composition during androgen deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Transperineal brachytherapy in patients with large prostate glands.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Management of metastatic prostatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

13 August 2018

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 November 2018

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049943

30 November 2018

Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and classification of diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20124400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3322/CAAC.20061

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

25 June 2018

http://europepmc.org/abstract/PMC/3049943

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55192988&oldid=1856168478"